New medicine to treat infections in adults
Vabomere, a combination of an antibiotic and new beta-lactamase inhibitor, addresses bacterial resistance
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Vabomere (meropenem trihydrate/vaborbactam), a new treatment option against the following infections in adults:
- Complicated urinary tract infection, including pyelonephritis, a sudden and severe infection causing the kidneys to swell and which may permanently damage them;
- Complicated intra-abdominal infection;
- Hospital-acquired pneumonia, including ventilator associated pneumonia;
- Bacteria in the blood associated with any of the infections listed above;
- Infections due to aerobic Gram-negative organisms in adults with limited treatment options.
The lack of availability of medicines to treat patients with infections caused by resistant bacteria has become a major problem in recent years. It is estimated that at least 25,000 patients in the European Union (EU) die each year from infections due to bacteria that are resistant to many medicines.
Vabomere is a fixed combination of vaborbactam, a new beta-lactamase inhibitor and meropenem, a broad-spectrum antibiotic belonging to the class of carbapenems that is already approved for use in the EU. It is a powder for concentrate for solution for infusion (drip into a vein).
Resistance to carbapenems has been increasing lately, in particular in Gram-negative bacteria, and is of major concern. Beta-lactamases are enzymes involved in bacterial resistance to these antibiotics. By inhibiting the action of beta-lactamases, vaborbactam protects meropenem from being inactivated and restores its activity against many, but not all, carbapenem-resistant pathogens.
In the clinical development program, the exposure to vaborbactam at the recommended dose was shown to be sufficient to protect the activity of meropenem against carbapenem-resistant Enterobacteriaceae. The CHMP also agreed that the studies did not indicate any major concerns regarding the safety profile of meropenem-vaborbactam.
EMA contributes to the European and global effort to tackle antimicrobial resistance. A major area of activity is to create an environment that stimulates and facilitates the development of new antimicrobials. The Agency’s activities also include the monitoring and analysis of data on antimicrobials to guide policy and research, as well as the promotion of their responsible use.
The opinion adopted by the CHMP is an intermediary step on Vabomere’s path to patient access. The opinion will now be sent to the European Commission for the adoption of a decision on an EU-wide marketing authorisation. Once the marketing authorisations has been granted, decisions about price and reimbursement will take place at the level of each Member State, taking into account the potential role/use of this medicine in the context of the national health system of that country.
- The applicant for is Rempex London Ltd.
|New medicine to treat infections in adults||(English only)||21/09/2018|
Latest News from
COVID-19: Member states need to harmonise health assessments and measures18/09/2020 16:33:00
Common definitions, health criteria and methodologies are key to effectively fighting the ongoing pandemic and its economic consequences in the EU, MEPs say.
Poland: Council has to “finally act” to protect minorities and the rule of law18/09/2020 15:25:00
Disrespect for judicial independence and the rights of LGBTI persons point to “overwhelming evidence” of breaches of EU values, Parliament says.
COVID-19 vaccines: Public hearing in European Parliament18/09/2020 14:33:00
Addressing the challenges linked to securing access to safe COVID-19 vaccines will be the main topic of an online hearing on 22 September from 09.00-12.00 in the European Parliament.
Parliament requests more support for regions to make energy transition a success18/09/2020 13:25:00
MEPs are ready to start negotiations with the Council on setting up the Just Transition Fund to mitigate the social impact of greening the economy.
European Green Deal Call: €1 billion investment to boost the green and digital transition18/09/2020 12:38:00
The European Commission yesterday decided to launch a €1 billion call for research and innovation projects that respond to the climate crisis and help protect Europe's unique ecosystems and biodiversity.
EU arms exports: need for more control and transparency18/09/2020 11:33:00
EU citizens have to be better informed about their governments’ strategic choices on an issue that directly affects their security, warn MEPs.
COVID-19: EU must step up efforts to tackle medicine shortages18/09/2020 10:38:00
Parliament calls for the EU to be more self-sufficient when it comes to medicines and medical equipment so that affordable treatments are available at any time.
Parliament says shipping industry must contribute to climate neutrality18/09/2020 09:25:00
To decarbonise maritime transport, Parliament voted to include CO2 emissions from the sector in the EU Emissions Trading System.
Vote on Own Resources: MEPs clear way for COVID-19 recovery plan17/09/2020 16:33:00
MEPs accelerate the procedure that will enable the EU to borrow €750 billion for the “Next Generation EU” recovery plan.